Skip to main content
Clinical Trials/NCT05962099
NCT05962099
Recruiting
Not Applicable

Defining Circadian Metabolism in Non-alcoholic Fatty Liver Disease

University of Oxford1 site in 1 country31 target enrollmentMarch 1, 2021
ConditionsNAFLD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
NAFLD
Sponsor
University of Oxford
Enrollment
31
Locations
1
Primary Endpoint
Change in hepatic fatty acid synthesis as measured by incorporation of 2H2 palmitate from 2H2O into very low density lipoprotein triglyceride (VLDL-TG) between morning and evening
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The investigators will conduct an open label, experimental medicine study exploring the diurnal patterns of hepatic lipid metabolism in NAFLD and non-NAFLD participants (determined by Transient elastography (TE) with controlled attenuation parameter (CAP)). We will also determine whether the diurnal patterns of lipid metabolism in NAFLD participants can be modified using lifestyle and weight loss intervention. Fourteen participants without NAFLD will have morning and evening metabolic investigations (visit 1M & 1E) to assess for changes in lipid flux pathways across the course of the day. After morning and evening investigations their involvement in the clinical study will then end. Seventeen NAFLD participants will also have identical baseline morning and evening investigation after which they will be enrolled into a 12-week lifestyle and weight loss programme. After 12-weeks, all 17 participants with NAFLD will have a follow up CAP, and morning and evening metabolic investigations (visit 2M & 2E).

Registry
clinicaltrials.gov
Start Date
March 1, 2021
End Date
June 1, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female
  • BMI 25-50 kg/m2
  • Age 18-75 years

Exclusion Criteria

  • A diagnosis of type 1 diabetes
  • Type 2 diabetes controlled with medications other than metformin (within last 3 months)
  • Shift working patterns in last 3-months or if likely to work shifts during study period.
  • Current or recent (\<3-months) use of weight loss medications
  • Current or recent use of oral contraceptive pill or hormone replacement therapy (within last 3-months)
  • Pregnancy
  • A blood haemoglobin \<120mg/dL
  • History of alcoholism or a greater than recommended alcohol intake (Recommendations \> 21 units on average per week for men and \> 14 units on average per week for women)
  • Haemorrhagic disorders
  • Treatment with anticoagulant agents

Outcomes

Primary Outcomes

Change in hepatic fatty acid synthesis as measured by incorporation of 2H2 palmitate from 2H2O into very low density lipoprotein triglyceride (VLDL-TG) between morning and evening

Time Frame: 12 hours

Secondary Outcomes

  • Difference in morning and evening glucose production and disposal (of a labelled stable isotope tracer) during a two-step hyperinsulinaemic-euglycaemic clamp(12 hours)
  • Difference in morning and evening glucose oxidation measured by incorporation of 13C in breath CO2 across a 2-step hyperinsulinemia euglycaemic clamp(12 hours)
  • Changes in diurnal patterns of hepatic fatty acid synthesis after weight loss programme (measured by incorporation of 2H2 palmitate from 2H2O into very low density lipoprotein triglyceride (VLDL-TG)(12 weeks)

Study Sites (1)

Loading locations...

Similar Trials